Bristol-Myers Squibb Company (NYSE:BMY) FY Conference Transcript

Summary of Bristol-Myers Squibb Company (NYSE:BMY) FY Conference Call Company Overview - Company: Bristol-Myers Squibb Company (BMY) - Event: TD Cowen's 46th Annual Healthcare Conference - Date: March 02, 2026 Key Points Industry and Market Dynamics - 2025 Performance: Strong performance with good momentum into 2026, particularly from growth portfolio products like REVLIMID, Breyanzi, and CAMZYOS [3][4] - Headwinds: Full generics for REVLIMID and POMALYST are now in the market, impacting legacy portfolio revenue, but significant growth is expected from ELIQUIS [3][4] - Operating Expenses: Disciplined management of operating expenses, with a normalization expected in 2026 after higher expenses in the second half of 2025 due to partnerships and acquisitions [4][5] Product Performance - CAMZYOS: Annualized over $1 billion in sales, with consistent increases in new patients and prescribers, indicating strong market adoption despite competition [6][7] - Opdivo Qvantig: Positive performance with expectations to achieve a 30%-40% conversion rate by 2028, improving practice efficiency and patient experience [8][9] - Cobenfy: Good progress in its first year, with a focus on increasing prescriber adoption and upcoming data from a phase 4 switching study expected to enhance market penetration [10][11] Upcoming Trials and Data Readouts - Alzheimer's Disease Psychosis Trials: Three studies (ADEPT 1, 2, and 4) are expected to read out by the end of 2026, with confidence in the product's efficacy based on previous studies [16][17] - Milvexin: Anticipated data readouts in SSP and AFib by the end of 2026, with potential to become a new standard of care in atrial fibrillation due to a better bleeding profile compared to ELIQUIS [27][28] Future Growth Potential - Admilprant: Positioned for significant market potential in IPF and PPF, with expectations that the market could grow from $4 billion to between $8 billion and $10 billion due to improved diagnosis and treatment rates [36][38] - Pipeline Assets: Multiple assets expected to read out by the end of 2026, including Cobentfy, Milvexin, Iberidone, and Ibertamide, all showing strong commercial potential [33][35] Strategic Focus - Long-term Growth Strategy: The company aims to be the fastest-growing in the industry by the end of the decade, with a focus on sustainable growth through a diverse pipeline of products [51][52] - Intellectual Property Defense: Commitment to vigorously defend IP for key products like Opdivo, with a conservative planning date for loss of exclusivity set for December 2028 [43][44] Conclusion - Overall Outlook: Bristol-Myers Squibb is positioned for strong growth with a robust pipeline and strategic focus on long-term sustainability, aiming to leverage upcoming data readouts and market opportunities to enhance its competitive position in the pharmaceutical industry [52][53]